ClinicalTrials.gg
CompletedNCT05934526Updated May 19, 2026

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

A Phase 3 interventional study of Placebo and Seralutinib in Pulmonary Arterial Hypertension, sponsored by GB002, Inc.. Completed at 166 sites in 31 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by GB002, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
17th of 253
390 · median 40
Started
2023
with 15 others
Phase 3
68 of 312
7 open now
Registered
275th of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 17th largest by enrollment of the 253 interventional ones that give a count, is one of 16 that started in 2023, is one of 68 in phase 3, and was the 275th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • seralutinib
  • GB002
  • PROSERA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subjects aged 18 to 75 years.
  2. (BMI) ≥ 15 kg/m\^2 and ≤ 40 kg/m\^2.
  3. Diagnosis of PAH classified by one of the following:

    1. Idiopathic PAH (IPAH) or heritable PAH (HPAH).
    2. PAH associated with connective tissue disease (CTD-APAH); PAH associated with anorexigen or PAH associated with methamphetamine use.
    3. Congenital heart disease with simple systemic to pulmonary shunt at least 1 year after surgical repair.
  4. 6MWDs ≥ 150 meters and ≤ 475 meters during Screening prior to randomization.
  5. WHO FC II or III.
  6. US Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) Lite 2 Risk Score ≥ 5 OR NT-proBNP ≥ 300 ng/L OR PVR ≥ 800 dyne s/cm\^5.
  7. Cardiac catheterization within the screening period, or a standard of care right heart catheterization (RHC) (with pressure wave forms available for review) up to 48 weeks prior to Screening.

    1. Mean pulmonary arterial pressure (mPAP) > 20 mmHg (at rest), AND
    2. Pulmonary vascular resistance (PVR) ≥ 400 dyne·s/cm\^5, AND
    3. Pulmonary capillary wedge pressure (PCWP) or left ventricle end-diastolic pressure (LVEDP) ≤ 15 mmHg.
  8. Treatment with at least one allowed background PAH disease-specific medication prior to Screening.

    1. Subjects receiving treatment with endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, guanylate cyclase stimulators, and/or prostacyclin analogues or prostacyclin receptor agonists are eligible only if on a stable dose for at least 12 weeks prior to and throughout Screening.
    2. Subjects receiving treatment with sotatercept are eligible only if on a stable dose of sotatercept for at least 24 weeks prior to and throughout Screening, with a RHC performed during Screening (or within 2 weeks prior to Screening).
  9. Pulmonary function tests (PFTs) at Screening or completed no more than 12 weeks prior to Screening.
  10. Women of (WOCBP) must have a negative pregnancy test at Screening and on Day 1 before first administration of Product (IP).
  11. WOCBP who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of from consent through 30 days following the last administration of IP.
  12. Male subjects: Non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of chronic thromboembolic disease or acute pulmonary embolism.
  2. Uncontrolled systemic hypertension as evidenced by systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg.
  3. Systolic blood pressure \< 90 mm Hg during Screening.
  4. WHO Pulmonary Hypertension Group 2 - 5.
  5. (HIV)-associated PAH, schistosomiasis associated PAH, PAH associated with portal hypertension, or pulmonary veno-occlusive disease (PVOD).
  6. Recent history of left-sided heart disease and/or cardiac disease within 48 weeks of Screening.
  7. (LVEF) ≤ 50% within 24 weeks of Screening.
  8. Hemodynamically significant valvular heart disease or uncontrolled symptomatic coronary disease.
  9. History of atrial septostomy.
  10. Uncontrolled atrial fibrillation or paroxysmal atrial fibrillation.
  11. Untreated severe obstructive sleep apnea.
  12. Hepatic dysfunction defined as Class A or higher, or as evidenced by one of the following at Screening: (ALT) or aspartate aminotransferase (AST) > 1.5 x (ULN) or total ≥ 1.5 x ULN.
  13. Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or IP administration (eg, history of intracranial hemorrhage, recurrent syncope).
  14. Any musculoskeletal disease, injury, or any other disease that limits evaluation of 6MWT.
  15. Initiation of an exercise program for cardiopulmonary rehabilitation within 12 weeks prior to Screening or planned during the study.
  16. Pregnant or nursing or intends to become pregnant during the duration of the study.
  17. Body weight \< 37 kg at Screening.
  18. Estimated (eGFR) \< 45 mL/min/1.73m\^2 (Hgb) concentration \< 8.5 g/dL at Screening.
  19. Evidence of active or latent Human immunodeficiency virus (HIV), or , or tuberculosis (TB) infection at Screening.
  20. Prior/concurrent treatment with tyrosine kinase inhibitors or activin signaling inhibitors:

    1. Tyrosine kinase inhibitors, other than Janus kinase inhibitors approved for systemic rheumatic diseases, within 12 weeks prior to Screening.
    2. Activin signaling inhibitors within 5 half-lives prior to Screening.
  21. Requirement of IV inotropes (ie, levosimendan, dopamine, dobutamine, milrinone, norepinephrine) or IV diuretics for more than 24 hours within 4 weeks prior to Screening.
  22. Subjects currently receiving oral anticoagulants (ie, warfarin/other vitamin K antagonists or direct-acting oral anticoagulants [DOACs]) if any of the following criteria are met:

    a. History within 24 weeks of Screening of: i. Syncope, or ii. Symptomatic bleeding in a critical area or organ iii. Intramuscular with compartment syndrome, or iv. Bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (20 g/L or greater) or more, or v. Bleeding leading to a transfusion of 2 U or more of whole blood or red blood cells.

    b. History of central nervous system pathology.

    c. History of clinically significant (massive) hemoptysis.

    d. If on warfarin/other vitamin K antagonist, uncontrolled (eg, INR > 3) as assessed.

    e. count \< 150 x 10\^9/L at Screening.

    f. Concomitant use of antiplatelet agents.

    g. CTD-APAH

    h. Concomitant use of sotatercept.

  23. Prior participation in seralutinib studies and/or prior treatment with seralutinib.
  24. Currently participating in or has participated in a study of an agent or has used an investigational device for the treatment of PAH within 12 weeks or 5 half-lives of the investigational agent, whichever is longer, prior to Screening.
  25. Current use of inhaled tobacco- or nicotine-containing products (including e-vapor products) and/or inhaled marijuana.
  26. Current alcohol use disorder based on the opinion of the Investigator, and/or a positive test for drugs of abuse.
  27. Subjects with a history of severe milk protein allergy or known intolerance to lactose.
  28. corrected for heart rate using Fridericia's formula (QTcF) of > 500 msec.
  29. Have any other condition or reason that, in the opinion of the Investigator or in the opinion of the Sponsor's Medical Monitor (MM) (or designee) in consultation with the Investigator, would prohibit the subject from participating in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
390 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo inhaled orally twice daily (BID) up to 48 weeks

    Drug: Placebo · Device: Generic Dry Powder Inhaler

  • Experimental
    Seralutinib 90 mg

    Seralutinib inhaled orally BID up to 48 weeks

    Drug: Seralutinib · Device: Generic Dry Powder Inhaler

Interventions

  • DrugPlacebo

    Matching capsule containing placebo

  • Capsule containing seralutinib

  • DeviceGeneric Dry Powder Inhaler

    Generic dry powder inhaler for seralutinib or placebo delivery

06

What researchers measure

Primary outcomes

  1. Change in distance achieved on the six-minute walk test (6MWT), six-minute walk distance (Δ6MWD) from baseline to Week 24

    Time frame: Baseline to 24 weeks

Secondary outcomes

  1. Time to first event of Clinical Worsening from first dose of Investigational Product (IP) through end of study

    Time frame: Baseline to 48 weeks

  2. Proportion of subjects who achieve all of the following components of clinical improvement at Week 24, in the absence of clinical worsening:

    1. Improvement from baseline in World Health Organization (WHO) functional class (FC) or maintenance of WHO FC II 2. Decrease from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) of ≥ 30% or decrease and maintenance at \< 300 ng/L 3. Increase from baseline in 6MWD of ≥ 10% or ≥ 30 m

    Time frame: Baseline to 24 weeks

  3. Change in NT-proBNP from baseline to Week 24

    Time frame: Baseline to 24 weeks

  4. Proportion of subjects with ≥ 1 point decrease from baseline in US Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) Lite 2 Risk Score at Week 24

    Time frame: Baseline to 24 weeks

  5. Proportion of subjects with each of the Clinical Worsening Outcomes:

    1. Death (all causes) 2. Hospitalization for signs and symptoms of worsening PAH (≥ 24 hours) 3. Worsening-related listing for or receipt of lung and/or heart/lung transplantation 4. Atrial septostomy performed 5. Worsening PAH requiring initiation of therapy with an additional approved background PAH disease-specific medication or the need to increase the dose of parenteral (IV or subcutaneous infusion) prostacyclin by 10% or more 6. Disease progression, defined by both of the following events occurring at any time, even if they began at different times, as compared to their baseline values: 1. Decrease in 6MWD of ≥ 15% on two consecutive tests, performed a minimum of 4 hours but no more than 1 week apart AND 2. Worsened WHO FC

    Time frame: Baseline to 52 weeks

  6. Proportion of subjects who improve from baseline in WHO FC or maintain WHO FC II

    Time frame: Baseline to 24 weeks

  7. Change in PAH-SYMPACT™ from baseline to Week 24

    Time frame: Baseline to 24 weeks

  8. Change in Euro-QoL - 5 Dimensions - 5 Levels (EQ-5D-5L) from baseline to Week 24

    Time frame: Baseline to 24 weeks

  9. Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs (SAEs), and treatment-emergent adverse events of special interest (AESIs)

    Time frame: Baseline to 52 weeks

07

Study locations

166 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Valley Advanced Lung Diseases Institute
    Fresno, California 93711, United States
  • Keck Medical Center of USC
    Los Angeles, California 90033, United States
  • Dept of Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
  • UC Davis Health
    Sacramento, California 95817, United States
  • Stanford Healthcare
    Stanford, California 94305, United States
  • Winchester Center for Lung Disease
    New Haven, Connecticut 06519, United States
  • The George Washington University Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
    Atlanta, Georgia 30309, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northside Hospital Laboratory - Atlanta
    Atlanta, Georgia 30342, United States
  • UI Health Hospital
    Chicago, Illinois 60612, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Norton Hospital
    Louisville, Kentucky 40202, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • M Health Fairview University of Minnesota Medical Center - East Bank
    Minneapolis, Minnesota 55455, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Duke University Medical Center - Duke South
    Durham, North Carolina 27710, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • INTEGRIS Cardiovascular Physicians, LLC
    Oklahoma City, Oklahoma 73112, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • The Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Temple Heart and Vascular Institute (Outpatient Clinic)
    Philadelphia, Pennsylvania 19140, United States
  • UPMC Presbyterian Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina - Nexus Research Center
    Charleston, South Carolina 29425, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • CHI St. Luke's Health Baylor College of Medicine Medical Center
    Houston, Texas 77030, United States
  • Houston Methodist Outpatient Center
    Houston, Texas 77030, United States
  • Baylor Scott & White Medical Center - The Heart Hospital
    Plano, Texas 75024, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
  • Advocate Aurora Health-Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Froedtert Hospital/Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Cardiologia Palermo
    Buenos Aires, Argentina
  • Instituto Cardiovascular de Buenos Aires
    Buenos Aires, Argentina
  • Instituto de Cardiologia de Corrientes Juana Francisca Cabral
    Corrientes, Argentina
  • Hospital Privado Centro Medico de Cordóba S.A.
    Córdoba, Argentina
  • Instituto de Investigaciones Clinicas Quilmes
    Quilmes, Argentina
  • Instituto Medico Rio Cuarto
    Río Cuarto, Argentina
  • Sanatorio Parque S.A.
    Rosario, Argentina
  • Hospital Provincial Dr. José María Cullen
    Santa Fe, Argentina
  • St Vincent's Hospital
    Melbourne, Victoria 3065, Australia
  • Wesley Research Institute
    Auchenflower, Australia
  • Royal Hobart Hospital
    Hobart, Australia
  • Nepean Hospital
    Kingswood, Australia
  • Religious Hospital Linz GmbH
    Linz, Austria
  • AKH-Vienna Medical Univesity of Vienna Internal Medicine II-Cardiology
    Vienna, Austria
  • Hôpital Erasme
    Anderlecht, Belgium
  • University Hospitals of Leuven (Campus Gasthuisberg)
    Leuven, Belgium
  • Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa
    Belo Horizonte, Brazil
  • Complexo de Prevencao, Diagnostico, Terapia e Reabilitacao Respiratoria - Hospital Dia do Pulmao
    Blumenau, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, Brazil
  • Uniao Brasileira de Educaçao e Assistência Hospital São Lucas da PUCRS
    Porto Alegre, Brazil
  • Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, Brazil
  • Núcleo de Gestão de Pesquisa/Hospital São Paulo - SPDM/UNIFESP
    São Paulo, Brazil
  • London Health Science Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y4W7, Canada
  • Peter Lougheed Center
    Calgary, Canada
  • University Health Network
    Toronto, Canada
  • Enroll SpA
    Santiago, Santiago Metropolitan 7500587, Chile
  • Centro de Investigacion Clinica UC-CICUC
    Santiago, Chile
  • Fundación Abood Shaio
    Bogotá, Colombia
  • Fundación Neumologica Colombiana
    Bogotá, Colombia
  • Institut Klinicke a Experimentalni Mediciny
    Prague, Czechia
  • Všeobecná fakultní nemocnice v Praze Il. interní klinika kardiologie a angiologie VFN a 1.LF UK Centrum pro plicní hypertenzi
    Prague, Czechia
  • Aarhus Universitetshospital, Department of Cardiology
    Aarhus, Denmark
  • Rigshospitalet, Department of Cardiology
    Copenhagen, Denmark
  • CHU Bicêtre
    Le Kremlin-Bicêtre, France
  • Institut Coeur Poumon
    Lille, France
  • CHU de Montpellier
    Montpellier, France
  • Hôpital Pasteur
    Nice, France
  • CHU de Poitiers
    Poitiers, France
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, France
  • Centre Hospitalier Universitaire - Hôpital d´Adultes de Brabois
    Vandœuvre-lès-Nancy, France
  • DRK Kliniken Berlin Westend
    Berlin, Germany
  • Zentrum fur Pulmona le Hypertonie, Klini k Ill fur lnnere Medizin (Kardiologie, Pneumologie, lnternlstische lntensiv medizin), Herzzentrum der Universitat zu Koln
    Cologne, Germany
  • Universitatsklinikum Dresden, Medizinische Klinik / Pneumologisches Studiensekretariat
    Dresden, Germany
  • Universitatsklinikum Giessen und Marburg GmbH Zentrum fur Innere Medizin, Med. Klinik und Poliklinik II Studienambulanz fur Pulmonale Hypertonie
    Giessen, Germany
  • Universitätsklinikum Greifswald Klinik und Poliklinik für Innere Medizin B
    Greifswald, Germany
  • Universitätsklinikum Halle (Saale) / Martin-Luther-Universität Halle- Wittenberg, Universitätsklinik und Poliklinik für Innere Medizin I
    Halle, Germany
  • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg Zentrum für pulmonale Hypertonie
    Heidelberg, Germany
  • Krankenhaus Neuwittelsbach
    Munich, Germany
  • Klinikum der LMU Medizinische Klinik und Poliklinik V
    München, Germany

Showing the first 100 of 166 sites across 31 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Sitbon O, Sahay S, Escribano Subias P, Zolty RL, Kingrey JF, Ryan JJ, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP, Ghofrani HA, Hemnes AR, McLaughlin VV, Vachiery JL, Zamanian RT, Ter Veer A, Roscigno RF, Mottola D, Parsley E, Aranda R, Zisman LS, Howard LS; TORREY Study Investigators. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study. Adv Ther. 2025 Oct;42(10):5104-5123. doi: 10.1007/s12325-025-03297-2. Epub 2025 Aug 11. PubMed 40788460 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Nov 2025, 22 months.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 22 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 7, 2023
StartActual
Dec 28, 2023
Primary completionActual
Nov 27, 2025
CompletionActual
Dec 22, 2025
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05934526
Lead sponsor
GB002, Inc.
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Dec 28, 2023
Primary completion
Nov 27, 2025
Completion
Dec 22, 2025
Last update
May 19, 2026

Study contacts

Richard Aranda, MD
study director · Gossamer Bio USA, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seralutinib

Start the discussion